Tanox has reported 48-week results from its Phase II clinical trial of HIV drug candidate, TNX-355. Following previously reported 24-week data, the new results show that HIV-infected patients who received either study dose of TNX-355, in combination with an optimized background regimen (OBR), maintained a considerably greater reduction in viral load than did patients given placebo
in combination with OBR.
At 48 weeks, treatment with a 10 mg/kg dose of TNX-355 resulted in a mean viral-load reduction of 0.96 log10, compared with a 0.14 log10 reduction in the placebo group, representing a 0.82 log10 greater reduction in viral load. Patients who received a 15 mg/kg dose of TNX-355 had a mean viral-load reduction of 0.71 log10, compared with a 0.14 log10 reduction
in the placebo group, representing a 0.57 log10 greater reduction in viral load.
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
CoreLink’s 3D Anterior Lumbar Approved by FDA
The implant allows for better imaging by minimizing material density.
Endo Resumes Lawsuit Against FDA Over Bulk Drug Compounding Decree
The company claimed the agency’s handling of bulk compounding laws violates the 2013 Drug Quality and Security Act, treating the laws as non-binding guidance rather than a legal mandate.